Leads Patients Pharmacology Side effects 
Legacy MEDSearch
JUNE 15, 2023
“At Cala, we’ve always been committed to expanding patient access and accelerating innovation in TAPS therapy for indications beyond essential tremor,” said Renee Ryan, CEO at Cala. “By By expanding into Parkinson’s disease, we are now able to bring this powerful treatment to additional patients who suffer from action hand tremors.”
European Pharmaceutical Review
JANUARY 11, 2024
The current medications (opioid and non-opioid) often force the patients to make an unfortunate choice between efficacy and debilitating side effects, leading to a cycling through multiple different therapies and suboptimal treatment response. The present unmet needs within chronic pain are not met with opioid therapies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
NOVEMBER 17, 2022
This marks the first update to NICE’s endometriosis guidelines since 2017, representing a huge milestone for patients and practitioners alike. This delay in diagnosis ultimately leads to disease progression and associated complications, such as chronic pelvic pain and infertility, which greatly affects the patients’ quality of life.
Legacy MEDSearch
DECEMBER 12, 2022
Highmark), one of America’s leading health insurance organizations and an independent licensee of the Blue Cross Blue Shield Association, will conduct a targeted Coverage with Evidence program with the goal of providing its members with affordable treatment for episodic and chronic migraine. .
Rep-Lite
DECEMBER 7, 2023
Education Requirements Many pharmaceutical companies prefer pharmaceutical sales candidates with a bachelor’s degree in a relevant field, such as biology, chemistry, pharmacology, or a healthcare-related discipline. You should be able to discuss the benefits, side effects, and uses of the medications with healthcare professionals.
European Pharmaceutical Review
SEPTEMBER 22, 2023
Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. Treatment with the mAbs delayed cognitive decline by 2.6 percent and 14.3
Pharmaceutical Technology
FEBRUARY 17, 2023
In January, amidst calls to improve patient safety by optimizing licensed drug formulations, the FDA released a draft guidance that signalled a departure from the most commonly used method of identifying a new therapy’s ideal dosage. For this approach, a “3+3” model is used where a study enrolls three patients into a given dose cohort.
Expert insights. Personalized for you.
98 
Let's personalize your content